Globus Medical Reports Preliminary Q4 Sales $657M, Up 6.6% YoY; FY24 Sales $2.52B, Up 60.6% YoY; Sees 2025 Revenue $2.66B-$2.69B Vs $2.67B Est.; Non-GAAP EPS $3.40-$3.50 Vs $3.42 Est.
Globus Medical Reports Preliminary Q4 Sales $657M, Up 6.6% YoY; FY24 Sales $2.52B, Up 60.6% YoY; Sees 2025 Revenue $2.66B-$2.69B Vs $2.67B Est.; Non-GAAP EPS $3.40-$3.50 Vs $3.42 Est.
Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The company anticipates fourth quarter 2024 sales of approximately $657.0 million, an increase of 6.6 percent over the fourth quarter 2023 on an as-reported basis. Full year 2024 sales are expected to be approximately $2.52 billion, an increase of 60.6 percent over the prior year on an as-reported basis.
Globus Medical, Inc. (紐交所:GMED),一家領先的肌肉骨骼解決方案公司,今天宣佈截至2024年12月31日的第四季度和全年的初步未經審計的銷售結果。該公司預計2024年第四季度銷售額約爲65700萬美元,比2023年第四季度增長6.6%。預計2024年全年銷售額約爲25.2億,比上一年增長60.6%。
The Company established its full year 2025 revenue guidance range of $2.66 billion to $2.69 billion and fully diluted non-GAAP earnings per share range between $3.40 to $3.50.
公司確定了2025年全年營業收入預期區間爲26.6億至26.9億,以及完全攤薄的非GAAP每股收益區間爲3.40至3.50美元。
譯文內容由第三人軟體翻譯。